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Background: Insulin enhancer binding protein-1 (ISL-1), a LIM-homeodomain transcription factor, is essential for
the heart, motor neuron and pancreas development. Recently, ISL-1 has been found in some types of human
cancers. However, how ISL-1 exerts the role in tumor development is not clear.
Methods and results: The expression of ISL-1 was assessed in 211 human lymphoma samples and 23 normal
lymph node samples. Immunohistochemistry results demonstrated a markedly higher expression of ISL-1 in 75%
of non-Hodgkin lymphoma (NHL) samples compared with that in normal lymph nodes or Hodgkin lymphoma
(HL) samples. CCK-8 analysis, cell cycle assay and xenograft model were performed to characterize the association
between ISL-1 expression level and biological functions in NHL. The results showed that ISL-1 overexpression obviously
promoted NHL cells proliferation, changed the cell cycle distribution in vitro and significantly enhanced xenografted
lymphoma development in vivo. Real-time PCR, Western blot, luciferase assay and ChIP assay were used to explore the
potential regulatory targets of ISL-1 and the results demonstrated that ISL-1 activated the c-Myc expression in NHL by
direct binding to a conserved binding site on the c-Myc enhancer. Further results revealed that ISL-1 could be positively
regulated by the c-Jun N-terminal kinase (JNK) and the Janus kinase/signal transducer and activator of transcription
(JAK/STAT) pathways. Both the JNK and JAK/STAT signaling inhibitors could significantly suppressed the growth of NHL
cells through the down-regulation of ISL-1 as demonstrated by CCK-8 and Western blot assays. Bioinformatic analysis
and luciferase assay exhibited that ISL-1 was a novel target of p-STAT3 and p-c-jun. ChIP, Co-IP and ChIP-re-IP analysis
revealed that ISL-1 could participate with p-STAT3 and p-c-Jun to form a p-STAT3/p-c-Jun/ISL-1 transcriptional complex
that binds directly on the ISL-1 promoter, demonstrating a positive feedback regulatory mechanism for ISL-1 expression
in NHL.
Conclusions: Our results provide the first evidence that ISL-1 is tightly linked to NHL proliferation and development by
promoting c-Myc transcription, and its aberrant expression was regulated by p-STAT3/p-c-Jun/ISL-1 complex activation.
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Malignant lymphoma is a group of hematological malig-
nancies, which includes Hodgkin lymphoma (HL) and
non-Hodgkin lymphoma (NHL). NHL make up around
90%, and HL account for the remaining 10% of all malig-
nant lymphomas [1]. NHL is generally classified according
to its origin, that is, B-cell NHL and T/NK-cell NHL.
The most common NHL subtypes by far in developed
countries are diffuse large B-cell lymphoma (DLBCL)
and follicular lymphoma (FL). All other NHL subtypes
have a frequency of less than 10% [1]. NHL is the seventh
most frequent cancer and the incidence rate has increased
markedly in recent years [2]. Although some progress is
being made, the fundamental abnormalities underlying
NHL still remain unclear. The molecular mechanisms
responsible for the etiology of NHL are poorly understood
and their elucidation could improve current therapeutic
approaches.
Insulin enhancer binding protein-1 (ISL-1) is a member
of LIM-homeodomain family. It is previously described to
play crucial roles in the development of heart, motor
neuron and pancreas [3-6]. Recent studies demonstrate
that ISL-1 is also involved in postnatal physiology and
pathology [7-9]. More reports indicate that ISL-1 may be
closely related to the occurrence of a variety of tumors.
High expression level of ISL-1 is detected in a majority of
pancreatic endocrine tumors [10], all four subtypes of lung
cancer [11], breast cancer [12], and nearly 65% of cholan-
giocarcinoma [13]. Most recent study indicates that ISL-1
is a sensitive but not entirely specific marker of pancreatic
neuroendocrine neoplasms (NENs) and their metastases.
The overall sensitivity and specificity of ISL-1 in identify-
ing primary pancreatic NENs is 88% and 80%, respectively
[14]. Increasing evidences indicate an important role of
ISL-1 in the development of some cancers. However,
whether ISL-1 has any functional effect on tumorigenesis
and how ISL-1 is regulated during cancer development
are yet not clear.
In the present study, we investigate whether ISL-1 plays
an oncogenic role in human tumors. We show that abnor-
mal high expression of ISL-1 is significantly correlated
with NHL and is specifically exhibited in 75% of human
NHL samples we examined. Aberrant ISL-1 is regulated
by p-STAT3/p-c-Jun/ISL-1 transcription complex and
potentiates NHL cells proliferation through up-regulating
c-Myc expression. Our findings reveal the feasibility of
ISL-1 as a potential therapeutic target for NHL treatment.
Results
ISL-1 is highly expressed in 75% of human NHL samples
In our pilot study, the specimens from different types of
tumors (colon, lung, breast, liver and ovarian neoplasms)
were analyzed by immunohistochemical staining. The
results showed a high expression level of ISL-1 in diffuselarge B cell lymphoma (DLBCL, the most common
lymphoma subtype and accounting for 30 ~ 40% of adult
non-Hodgkin lymphoma [15]), compared with reactive
lymph nodes (data not shown).
To examine the pathological relevance of ISL-1 in human
lymphoma development, we analyzed the expression level
and cellular distribution of ISL-1 in collected specimens
and tissue microarrays by immunohistochemical staining.
These tissue specimens included 23 normal lymph nodes
and 211 lymphoma samples. The lymphoma specimens
could be classified into two types: 195 NHL (159 B-cell
lymphoma, 36 T-cell lymphoma) and 16 Hodgkin lymph-
oma (HL). As summarized in Table 1, ISL-1 expression
level is markedly elevated in 75% of 195 NHL samples.
Only 3 cases of normal lymph nodes exhibited moderate
ISL-1 immunostaining, none of the 23 normal lymph nodes
or 16 HL showed any strong positive staining for ISL-1.
Figure 1A shows representative immunohistochemistry
images of ISL-1 staining in human normal lymph node,
HL and NHL. ISL-1 staining was predominantly detected
in the nuclear of a series of NHL lymphoma cells and, to a
much lesser extent, in the normal lymph nodes and HL
samples. Statistical analysis revealed that there was no
significant difference in the expression of ISL-1 between
normal lymph nodes and HL samples (p = 0.13), whereas,
the positive staining of ISL-1 was significantly correlated
with NHLs compared with that in normal lymph nodes
(p < 0.001) (Figure 1B).
Meanwhile, we found a predominant expression of ISL-1
in a variety of NHL cell lines (Figure 1C,D). These
data establish that ISL-1 expression is highly elevated
in the majority of NHLs and might be tightly linked to
lymphomagenesis.
ISL-1 promotes proliferation of NHL cells in vitro and
enhances xenografted lymphoma development in vivo
We have previously shown that ISL-1 promoted the pro-
liferation of adult pancreatic islets cells [6]. We wonder
whether up-regulated ISL-1 in NHL plays a role in promot-
ing NHL cells proliferation and tumorigenesis. Therefore,
Raji, Jurkat and Ly3 were electroporated with pcDNA3.1-
ISL1, or pLL3.7-ISL1-siRNA plasmid to establish stable
ISL-1 overexpressing or knockdown NHL cell lines. ISL-1
expression level in stably transfected NHL cell lines
was measured by Western blot analysis and the degree
of ISL-1 expression changes was analyzed by gray scanning
using Bio-Rad Quantity One software on the images from
3 independent experiments. The results showed that the
expression level of ISL-1 was ameliorated approximately 7
folds in ISL-1 overexpressed Raji cells (Additional file 1:
Figure S1A) and around 2.7 folds in ISL-1 overexpressed
Ly3 and Jurkat cells (Additional file 1: Figure S1B,C),
while the level of ISL-1 was attenuated to less than 10%
in ISL-1 knockdown Ly3 and Jurkat cells (Additional
Table 1 Immunohistochemistry of ISL-1 expression in non-Hodgkin lymphoma




B-cell lymphoma (n = 159)
DLBCL 139 2 24 113 81
Follicular Lymphoma 8 1 5 2 25
Mantle cell lymphoma 4 0 1 3 75
Burkitt lymphoma 3 0 1 2 67
Lymphoplasmacytic lymphoma 5 0 1 4 80
T-cell lymphoma 36 3 10 23 64
Total 195 6 42 147 75
*Positive percentage is determined by number of strong staining samples over the total number of samples.
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and knockdown cell lines are successfully established.
When ISL-1 protein level was up or down-regulated,
notable promotion or inhibition of cell growth were
observed in corresponding cell lines (Figure 2A). To
further determine the role of ISL-1 on proliferation of
NHL cells, the cell cycle profiles were analyzed. Compared
with the control, Raji, Ly3 and Jurkat cells with ISL-1-
overexpression showed a decreased cell population in G1Figure 1 ISL-1 is highly expressed in the majority subtypes of NHL. (A
and multiple subtypes of lymphoma specimens was performed. Representativ
samples are shown (200 ×). Scale bars = 100 μm. (B) Staining scores of ISL-1 in
(C to D) The mRNA and protein levels of ISL-1 in NHL cell lines and health hu
Western blot (D) analysis. Numbers 1–7 represent PBC samples from differentphase and a remarkably increased cell population in the S
and G2/M phases. Conversely, Ly3 and Jurkat cells with
ISL-1 knockdown exhibited an increase in the proportion
of cells in G1 phase and a decrease in the proportion of
cells in S and G2/M phases (Figure 2B). These results
indicate that ISL-1 could significantly change the cell
cycle dynamics and thus promote NHL cells proliferation.
To further confirm whether ISL-1 could promote tumor
growth in vivo, we used the SCID mice xenograft model) Immunohistochemistry for ISL-1 expression in normal lymph nodes
e images of ISL-1 expression level and cellular distribution in different
normal lymph nodes, HL and NHL were statistically analyzed by χ2 test.
man peripheral white blood cells (PBC) were analyzed by RT-PCR (C) and
donors.
Figure 2 ISL-1 promotes NHL cells proliferation and affects cell-cycle phase distributions. (A) The relative proliferation rate of stably transfected
cells was determined by CCK-8 assay at indicated time post-seeding. (B) Cell cycle distributions were analyzed by flow cytometry. The data represent
three independent experiments. Each bar represents mean ± SD. p values were calculated using a Student t-test (*p < 0.05, **p < 0.01, #p < 0.05,
##p< 0.01 vs. each control). (Control, ISL-1, Non-silencer and ISL-1 siRNA represent the cells transfected with pcDNA3.1, pcDNA3.1-ISL-1, pLL3.7-Non-silencer
or pLL3.7-ISL1-siRNA plasmid, respectively)
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ment. We found that the initiation and the growth of
tumor were significantly earlier and faster with ISL-1
overexpressing cells than those with the control cells
(Figure 3A,C). Conversely, the tumor growth was obvi-
ously impaired with ISL-1 knockdown cells (Figure 3B,D).
After the last measurement, the tumors were isolated
and weighed. The ISL-1-overexpressing cells produced
significantly larger and heavier tumors than the control
cells, in contrast, the ISL-1-knockdown cells produced
smaller and lighter tumors compared with the control
cells (Additional file 2: Figure S2). We further compared
the expression of ISL-1 in the tumor tissues isolated from
the mice. As shown in Figure 3E, the protein level of
ISL-1 in the tumors was positively correlated with the
tumor volumes in each group. Therefore, our animal
experiments confirm that ISL-1 potentiates NHL growth
in vivo.
Collectively, in vitro and in vivo results indicate that
overexpression of ISL-1 promotes NHL cells proliferation
and enhances lymphoma development, whereas knock-
down of ISL-1 attenuates NHL cells proliferation and
inhibits xenograft growth.
ISL-1 stimulates NHL cell proliferation through the
up-regulation of c-Myc expression
To explore the mechanism of ISL-1-stimulated NHL cell
proliferation, bioinformatic analysis was performed withprofessional MatInspector software and refFlat Database
to identify the downstream target genes of ISL-1. Several
putative genes, including CyclinD1, BCL-6 and c-Myc
were identified for further investigation, as these genes
contain conserved ISL-1 binding sequences (YTAATGR)
on the upstream of the ATG translation start site
[16-18]. More importantly, they are remarkably related to
the pathogenesis of NHL as previously reported [16-18].
However, the expression of CyclinD1 and BCL-6 did not
show a predicted correlation with ISL-1 in NHL cells (data
not shown). Therefore, we focused on c-Myc in the rest
investigations.
Western blot results showed that the basal expression
level of c-Myc was positively correlated with the expression
level of ISL-1 in NHL cell lines (will be discussed later in
Figure 4A). Moreover, further results indicated that the
overexpression of ISL-1 increased the expression of c-Myc
at both mRNA and protein levels in Raji cells (Figure 5A,
B left panel). Whereas, the significant decrease of c-Myc
expression was associated with the knockdown of ISL-1 as
compared with those in the control Ly3 cells (Figure 5A,B
right panel). These results show that ISL-1 could act as a
transcriptional activator of c-Myc.
Furthermore, we uncovered that c-Myc is a direct tran-
scriptional target of ISL-1. Bioinformatic analysis revealed a
conserved ISL-1 binding site (TAAT) at −1856 ~ −1852 bp
upstream of the ATG translation start site on the c-Myc
enhancer region (Figure 5C). Luciferase assay with c-Myc-
Figure 3 ISL-1 enhances xenografted lymphoma development in vivo. (A to D) NOD-SCID (nonobese diabetic/severe combined
immunodeficient) mice were injected s.c. with different NHL cells that were stably transfected with pcDNA3.1 (Control), or pcDNA3.1-ISL-1 (ISL-1)
construct (A,C), pLL3.7-Non-silencer or pLL3.7-ISL1-siRNA plasmid (B,D). The tumor size was monitored at indicated days post-injection. Statistical
analysis was carried out with 2-way ANOVA. (E) The mice were killed after the last measurement of tumor volume, whole-cell lysate of 2 tumor
samples of each group were prepared and subjected to Western blot analysis for ISL-1 level detection. GAPDH served as an internal control.
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binding site for ISL-1 on the c-Myc enhancer) showed the
stimulated c-Myc-luc activity in ISL-1-overexpressing cells
in a dose-dependent manner, whereas a significant decrease
of c-Myc-luc activity was seen in ISL-1-knockdown cells
(Figure 5D). The constructs containing the mutant or de-
leted ISL-1 binding site on the c-Myc enhancer (Figure 5C),
c-Myc-luc M1 (“TAAT” mutated to “cgAT”), c-Myc-luc
M2 (“TAAT” mutated to “cggc”), c-Myc-luc D1 (“TAAT”
with “TA” deleted) and c-Myc-luc D2 (“TAAT” completely
deleted), exhibited a significant decrease of luciferase
activity compared to the wild type c-Myc-luc (Figure 5E).
To determine if ISL-1 could occupy the c-Myc enhancer
region in vivo, a specific primer covering the potential
ISL-1 binding site located between −1935 and −1744 bp
of c-Myc enhancer were designed (Figure 5C) and used
for chromatin immunoprecipitation (ChIP) assay in Ly3
cells. As shown in Figure 5F, ISL-1 was recruited to the
c-Myc enhancer about four folds as compared with
IgG, suggesting that ISL-1 could bind on the c-Myc
enhancer in vivo. These results indicate that ISL-1 is a
direct regulator of c-Myc transcription in NHL cells.
Taken together, ISL-1 promotes NHL cells proliferation
possibly via the activation of the c-Myc enhancer and thus
increasing its expression.p-c-Jun and p-STAT3 contribute to the up-regulation of
ISL-1 expression in NHL cells
To explore the molecular regulatory mechanism for ISL-1
up-regulation, bioinformatic analysis was used to identify
the potential regulatory factors that could bind on the
transcriptional regulatory region of ISL-1. Relevant con-
served binding sites of symbolic transcriptional factors,
specifically pointing to major pathways such as WNT,
MAPK/ERK, p38 MAPK, SAPK/JNK and JAK/STAT,
were identified on the ISL-1 transcriptional regulatory
region. Previous reports show that ISL-1 is regulated by
or interacts with these signal pathways in different
physiological or pathological processes and all these signal
pathways could contribute to malignant progression of
NHLs [19-25]. However, whether the up-regulated ex-
pression of ISL-1 in NHLs is mediated by these signal
pathways needs to be elucidated.
To explore which signal pathway is involved in ISL-1
up-regulation in NHL, Western blot was used to analyze
the impact of inhibitors or activators of the above signaling
pathways on ISl-1 expression. The results showed that
both JNK signaling inhibitor SP600125 and JAK/STAT
signaling inhibitor STATTIC could notably reduce the
expression of ISL-1 at protein level. Other inhibitors or
activators exhibited little effect on the expression level
Figure 4 The expression of ISL-1 is positively correlated to the expression of p-STAT3, p-c-Jun and c-Myc. (A) NHL cell lines were
analyzed by Western blot with indicated antibodies. (B) Immunohistochemistry for ISL-1, p-STAT3, p-c-Jun and c-Myc expression were performed
in multiple specimens of normal lymph nodes (top panel) and NHL patients (bottom panel). Representative images of ISL-1, p-STAT3, p-c-Jun and
c-Myc expression levels and cellular distributions in different samples are shown (200 ×). Scale bars = 100 μm
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suppose that the expression of ISL-1 may be modulated
by JNK and JAK/STAT signal pathways.
As we known, p-c-Jun and p-STAT3 belong to JNK
and JAK/STAT signal pathways, respectively. They are the
most important functional activators for the signaling
transduction and closely link to lymphoma cell survival,
proliferation and transformation [21,24,26-29]. To verify
how ISL-1 is regulated by JNK and JAK/STAT signal
pathways, we first analyzed the basal expression levels
and correlations of p-c-Jun, p-STAT3, along with ISL-1
and the prominent oncogenic protein c-Myc in a series
of NHL cell lines and numbers of human NHL tissue
specimens. The results of Western blot showed that
the p-c-Jun and p-STAT3 were readily detectable and
positive consistent with the expression level of ISL-1
and c-Myc in all these cell lines (Figure 4A). We then
analyzed the expression of ISL-1, p-c-Jun, p-STAT3 and c-
Myc at protein level on 35 cases of human NHL and 10
cases of human normal lymph node by immunohistochem-
ical staining. As shown in Figure 4B, p-c-Jun, p-STAT3 andc-Myc staining were considerably stronger in NHL than in
normal lymph node, in parallel with the pattern observed
for ISL-1 in NHL. Pearson correlation analysis revealed that
the expression level of ISL-1 protein is strongly correlated
with p-STAT3, p-c-Jun and c-Myc protein levels in human
NHL samples surveyed (Pearson correlation coefficient
r = 0.737, 0.501, 0.803 respectively, all p < 0.001). These data
indicate that increased coexpression of ISL-1, p-STAT3, p-c-
Jun and c-Myc may be associated with the development of
NHL. The above results indicate that JNK and JAK/STAT
signaling pathways are likely to promote ISL-1 expression
through the constitutively activated p-c-Jun and p-STAT3.
Further analysis showed that the significantly increased
ISL-1 expression was positively associated with the activa-
tion of p-c-Jun or p-STAT3, after treated with JNK or JAK/
STAT activator (Anisomycin or IL-6). Conversely, after
treated with JNK or JAK/STAT inhibitor (SP600125 or
STATTIC), the expression of ISL-1 was obviously decreased
(Figure 6). These results show that persistent activation of
p-c-Jun and p-STAT3 lead to the aberrant transcription of
ISL-1 in NHL cells.
Figure 6 p-c-Jun and p-STAT3 contribute to ISL-1 overexpression in NHL cells. (A to B) real-time RT-PCR (A) and Western blot (B) show the
expression changes of ISL-1 in Raji and Ly3 cells after treated with JNK signaling pathway activator (Anisomycin, 15 ng/ml) or inhibitor (SP60012,
10 μM) for 6 h. (C to D) real-time RT-PCR (C) and Western blot (D) show the expression changes of ISL-1 in Ly3 cells after treated with JAK/STAT
signaling pathway activator (IL-6, 4 ng/ml) or inhibitor (STATTIC, 6 μM) for 24 h. Each bar represents mean ± SD from three samples. p values were
calculated using a Student t-test (*p < 0.05, vs. the control).
Figure 5 ISL-1 promotes the expression of c-Myc in NHL cell lines. (A to B) The expression of ISL-1 and c-Myc were analyzed at both mRNA and
protein levels by real-time RT-PCR (A) and Western blot (B) in Raji cells with stable ISL-1 overexpression and Ly3 cells with stable ISL-1 knockdown.
(C) Consensus binding site (TAAT box) for ISL-1 on the human c-Myc enhancer was analyzed by MatInspector software. The mutant sequences
are presented and they were used to construct mutant c-Myc-luc. (D to E) The transcriptional activity of ISL-1 on c-Myc-luc wide type (D), mutants or
deletions (E) was analyzed by luciferase reporter assay in HeLa cells. (“WT”, “M” and “D” represent the plasmid of c-Myc-luc wide type, mutant,
or deletion, respectively.). Non, WT and ctrl served as the control in corresponding experiments. (F) ISL-1 recruited on c-Myc promoter was
analyzed by ChIP assay. Soluble chromatin was prepared from Ly3 cells followed by immunoprecipitation with the antibody against ISL-1 and
the normal IgG served as a control. The DNA extractions were amplified using the primers that covered the ISL-1 binding sites on c-Myc enhancer
region by real-time PCR. The data represent 3 independent experiments, each performed in triplicate. Each bar represents mean ± SD. p values were
calculated using a Student t-test (*p < 0.05, **p < 0.01, #p < 0.05 vs. the control).
Zhang et al. Molecular Cancer 2014, 13:181 Page 7 of 15
http://www.molecular-cancer.com/content/13/1/181
Zhang et al. Molecular Cancer 2014, 13:181 Page 8 of 15
http://www.molecular-cancer.com/content/13/1/181Inhibition of JNK and JAK/STAT pathways suppresses NHL
cells proliferation via down-regulating ISL-1 expression
We have shown that both JNK and JAK/STAT signaling
inhibitors can suppress ISL-1 expression. However, it is
not clear whether these inhibitors could affect the prolifer-
ation of NHL cells by decreasing ISL-1 expression level.
CCK-8 analysis was firstly performed to analyze the
influence of JNK and JAK/STAT inhibitors on NHL cells
proliferation. As shown in Figure 7A, both SP600125 and
STATTIC could significantly decrease the proliferation
rate of NHL cells.
To further investigate whether ISL-1 was involved in
the inhibition of tumor cells proliferation mediated by
these inhibitors, Ly3 cells were treated with SP600125 orFigure 7 JNK or JAK/STAT signaling inhibitors inhibit NHL cells prolife
proliferation rate of lymphoma cell lines were measured using CCK-8 analy
or JAK/STAT signaling pathway inhibitor (STATTIC, 6 μM). The cell treated w
(10 μM) and STATTIC (6 μM) on ISL-1 and c-Myc expression at both mRNA (B
blot. The cells treated with DMSO at different time point were used as th
type or M1) was measured in Ly3 cells with or without ISL-1 transcfection afte
inhibition of Ly3 cells with or without ISL-1 transcfection was measured by CC
The data represent three independent experiments. Each bar represents mea
**p < 0.01, #p < 0.05, ##p < 0.01 vs. each control).STATTIC to inhibit the phosphorylation of c-Jun or
STAT3. As shown in Figure 7B, C and (Additional file 4:
Figure S4), a distinct decreased expression of ISL-1 was
correlated to SP600125 or STATTIC-induced inhibition
of p-c-Jun or p-STAT3. Additionally, the expression change
of c-Myc was also consistent with the change pattern
of ISL-1. These data indicate that the JNK and JAK/
STAT pathways regulate c-Myc expression and NHL
cells proliferation, which may be partly through the
regulation of ISL-1 expression.
To explore this further, luciferase assay was used to
analyze the impact of SP600125 or STATTIC on the
luciferase activity of c-Myc-luc. The inhibition of JNK and
JAK/STAT pathways significantly decreased c-Myc-lucration through down-regulating ISL-1 expression. (A) The relative
sis after treated with JNK signaling pathway inhibitor (SP60012, 10 μM)
ith DMSO were used as the control. (B to C) The effect of SP600125
) and protein levels (C) were analyzed by real-time RT-PCR and Western
e corresponding control. (D) The luciferase activity of c-Myc-luc (wide
r treated with 10 μM SP600125 or 6 μM STATTIC for 24 h. (E) The growth
K-8 analysis after treated with 10 μM SP600125 or 6 μM STATTIC for 24 h.
n ± SD. p values were calculated using a Student t-test (*p < 0.05,
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recover the effect mediated by the inhibitors of JNK and
JAK/STAT pathways (Figure 7D left panel). Whereas, the
mutant constructs c-Myc-luc M1 exhibited much smaller
extent of luciferase activity changes (Figure 7D right
panel). These results support that ISL-1 is involved in
the JNK and JAK/STAT regulation on c-Myc expression.
We next assessed whether the expression level of ISL-1
could influence the effects of p-c-Jun and p-STAT3 on
the proliferation rate of Ly3 cells. As shown in Figure 7E,
both p-c-Jun and p-STAT3 inhibitors could significantly
suppress the proliferation of Ly3 cells transfected with the
control vectors, while, the growth inhibition mediated
by p-c-Jun and p-STAT3 inhibitors could be rescued in
ISL-1-overexpressing cells, which further demonstrates
the effect of ISL-1 on the proliferation of cells.
Collectively, JNK and JAK/STAT signaling inhibitors
suppress NHL cells proliferation possibly through down-
regulating ISL-1 expression. Therefore, ISL-1 may serve
as a new target molecule for NHL treatment.
p-STAT3/p-c-Jun/ISL-1 forms a transcriptional complex
and binds directly to the ISL-1 promoter in NHL cells
The above results have shown that p-STAT3 and p-c-Jun
could increase the expression level of ISL-1 to promote
the proliferation of NHL cells. However, it is unknown
how p-STAT3 and p-c-Jun control ISL-1 expression. Bio-
informatic analysis showed that the core transcriptional
regulatory region of ISL-1 (−1000 ~ ATG) [30] contains
conserved p-STAT3 and p-c-Jun binding sites (Figure 8A).
Luciferase assay with ISL-1-luc, a ISL-1 luciferase reporter
construct containing the binding site of c-Jun and STAT3,
was performed in Ly3 cells treated with IL-6/STATTIC
(JAK/STAT signaling activator/inhibitor) or Anisomycin/
SP600125 (JNK signaling activator/inhibitor), respectively.
As shown in Figure 8B, ISL-1-luc activity was increased
in Anisomycin or IL-6 treated cells. Whereas a signifi-
cant decrease of ISL-1-luc activity could be observed
after SP600125 or STATTIC treatment. These results
further demonstrate that both JNK and JAK/STAT signal-
ing pathways are able to activate the ISL-1 transcription
effectively.
To confirm whether p-STAT3 and p-c-Jun bind to the
ISL-1 regulatory region, a set of primers covering the
ISL-1 promoter region between −994 and −216 were
designed for real-time PCR in ChIP assay (Figure 8A).
The ChIP analysis showed that p-STAT3 was recruited
to the region of ISL-1 promoter covered by primer 2
(−790 ~ −630) by approximately 12 folds (Figure 8C left
panel), and p-c-Jun was recruited to the region of ISL-1
promoter covered by primer 4 (−397 ~ −216) by about 6
folds (Figure 8C right panel), respectively, as compared
with primer 1 (−994 ~ −772) as the control. Interestingly,
we also observed magnificent enrichment of p-STAT3at the p-c-Jun binding region (primer 4 covered re-
gion, Figure 8C left panel), p-c-Jun at the p-STAT3
binding region (primer 2 covered region, Figure 8C
right panel), and both p-STAT3 and p-c-Jun at the
primer 3 (−613 ~ −373) covered region (Figure 8C left
and right panel). Therefore, we suppose that p-STAT3
possibly cooperate with p-c-Jun and synergistically
regulate ISL-1 expression in NHL cells.
According to previous reports, p-STAT3 could interact
with p-c-Jun to regulate MMP-1 [31], MMP-7 [32] or
other genes expression in human cancers [33]. Meanwhile,
the cooperation and co-localizations between p-STAT3
and ISL-1 [25,34], p-c-Jun and ISL-1 [23] are also authen-
ticated in different genes transcription. These evidences
promote us to hypothesize that p-STAT3, p-c-Jun and
ISL-1 may form a transcriptional activation complex that
regulates the expression of ISL-1 by direct binding to the
ISL-1 promoter.
To verify this hypothesis, co-immunoprecipitation (Co-IP)
and ChIP-re-IP were performed to analyze whether p-
STAT3, p-c-Jun and ISL-1 could form a complex and
bind directly on the ISL-1 promoter. Co-IP results
demonstrate that one component of the presumptive
complex could co-immunoprecipitate with all of the
other components, supporting the existence of this
complex (Figure 8D). Furthermore, ChIP-re-IP analysis
confirmed that p-STAT3, p-c-Jun and ISL-1 indeed
existed in the same protein complex and co-localized
on the primer 2 and primer 4 covered region of ISL-1
promoter (Figure 8E). These results reveal that p-STAT3,
p-c-Jun and ISL-1 could form a transcriptional activation
complex on the ISL-1 promoter, which further indicates
that there might be a positive feedback loop to contribute
to ISL-1 up-regulated expression in NHL cells.
To determine whether ISL-1 is involved in the positive
feedback loop on the ISL-1 transcription, luciferase assay
was performed with ISL-1-luc. As shown in Figure 8F, ISL-
1-luc activity was increased in a dose-dependent manner
in ISL-1-overexpressing Ly3 cells, indicating, for the first
time, that ISL-1 could promote its own expression in
NHL cells and therefore to form a positive feedback.
Collectively, these results indicate that ISL-1 may have a
positive feedback regulation: p-STAT3 and p-c-Jun up-
regulate ISL-1 expression, then ISL-1 form a complex with
p-STAT3 and p-c-Jun to participate ISL-1 overexpression.
The consequence is to promote the proliferation of
NHL cells.
Discussion
NHL is the most common lymphoid malignancy in adults,
accounting for ~70,000 new cases each year in the US [2].
The aggressive NHL, which is, pathophysiologically and
clinically, a very heterogeneous disease, differs significantly
in its dependence on signaling pathways, and responses
Figure 8 p-STAT3/p-c-Jun/ ISL-1 forms a transcriptional complex and binds directly to ISL-1 promoter. (A) Consensus binding sites for
p-STAT3 and p-c-Jun on the ISL-1 promoter were analyzed by Matinspector software. (B) The luciferase activity of ISL-1-luc was analyzed by luciferase
reporter assay in Ly3 cells after treated with IL-6 (4 ng/ml), STATTIC (6 μM), Anisomycin (15 ng/ml) or SP600125 (10 μM) for 24 h. (C) ChIP assay was
performed with anti-p-STAT3 Ab (left panel) or anti-p-c-Jun Ab (right panel) for immunoprecipitation using chromatin harvested from Ly3 cells. The
DNA extractions were amplified using the primers that cover the p-STAT3 (primers 2) or p-c-Jun (primers 4) binding sites, or control primers (primers 1,
3) on the ISL-1 promoter by real-time PCR with normal IgG as a control. (D) Co-IP assay was performed in Ly3 for the transcriptional complex recruited
on the ISL-1 promoter. (E) ChIP-re-IP assay was performed first with anti-ISL-1 Ab or rabbit IgG Ab and then with anti-p-STAT3, anti-p-c-Jun or IgG Abs
for immunoprecipitation using chromatin harvested from Ly3 cells. (F) The transcriptional activity of ISL-1 on ISL-1-luc was analyzed in Ly3 cells
by luciferase reporter assay. The data represent three independent experiments. Each bar represents mean ± SD. p values were calculated
using a Student t-test (*p < 0.05, **p < 0.01 vs. the control).
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common molecular target functionally associated with
non-Hodgkin lymphomagenesis is required to be identi-
fied to develop effective therapeutic approaches that will
improve the clinical outcome of patients with different
subtypes of NHL. In this study, we found that an elevated
expression of ISL-1 in 75% of NHL samples examined,
and further studies provided evidences that aberrant
expression of ISL-1 significantly correlated with NHLs
and might be a potential therapeutic target for NHL
treatment. However, the classification of NHL is very
complicated. According to the World Health Organization
(WHO) Classification, NHL could be classified into 36
subtypes (21 of B cell and 15 of T-cell type), excluding
entities of uncertain malignant potential [1]. The most
dominant forms of NHL are diffuse large B-cell lymph-
oma (about 30%) and follicular lymphoma (about 20%).All other NHL subtypes have a frequency of less than 10%
[1]. In parallel with the proportion of each NHL subtype,
we performed immunohistochemical analyses for ISL-1
in 195 primary lymphoma tissue specimens, including
159 B-cell lymphoma and 36 T-cell lymphoma samples.
As summarized in Table 1, ISL-1 was remarkably over-
expressed in 81% of 139 DLBCL samples. Meanwhile,
although strong positive staining for ISL-1 was identified
in 25% of 8 follicular lymphoma (FL) and 67% of 3 Burkitt
lymphoma samples, respectively, the total numbers of
those specimens examined were small and awaited larger
confirmatory studies. In the further study, we applied the
commonly used Raji (Burkitt cell line), Jurkat (T-cell
leukemia/lymphoma cell line) and Ly3 (DLBCL cell line)
in multiple experiments to represent NHLs [24,36,37].
However, it should not be ignored that the molecular
pathogenesis of each subtype are not completely identical,
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negative NHLs. Moreover, it has been reported that in
addition to de novo DLBCL, 30-40% of FL, a low-grade
NHL, will transform to an aggressive DLBCL [38,39].
According to the immunohistochemical analyses, we were
able to show a significantly elevated level of ISL-1 in the
vast majority (81%) of DLBCL. In contrast, we did not
observe significant changes of ISL-1 in most of the indo-
lent lymphoid malignancies examined, such as FL (25%),
indicating that ISL-1 expression level might be correlated
with the progression and degree of malignant NHLs.
We previously showed that ISL-1 could stimulate pan-
creatic islet cells growth and prevent adult pancreatic
islet cells from reactive oxygen species (ROS) induced
apoptosis [6]. In this study, we found that abnormally
up-regulated expression of ISL-1 in NHL cells obviously
facilitated cell proliferation in vitro and significantly
enhanced lymphoma development in vivo, providing the
first evidence that ISL-1 could promote non-Hodgkin
lymphomagenesis and specific disruption of ISL-1 could
be capable of inhibiting NHL cells with high endogenous
levels of ISL-1. Our previous report reveals that c-Myc
and CyclinD1 are novel downstream targets of ISL-1
and are involved in ISL-1 regulation on the proliferation
of adult islet cells [6]. However, in NHL cells, ISL-1 could
regulate c-Myc but had minimal effect on CyclinD1.
These implied that c-Myc must be a more potent down-
stream factor of ISL-1 to mediate proliferation effects in
lymphoma tumorigenesis.
The proto-oncogene c-Myc has been linked to a diverse
range of cellular functions, such as cell cycle regulation,
proliferation, differentiation and metabolism. Not sur-
prisingly, aberrant c-Myc signaling has been observed
to promote cell transformation and tumor progression
in human cancers [40]. According to previous reports,
c-Myc overexpression has not only been described as a
defining feature and the driving oncogene for Burkitt
lymphoma, but also been recognized in mantle cell
lymphoma (MCL), DLBCL and other NHLs [18,41-43].
c-Myc overexpression in human tumors has been attrib-
uted to transcriptional regulation, gene amplification, as
well as genomic translocation [40]. However, in most
NHLs, the reason for c-Myc up-regulated expression has
not been clearly elucidated. In this study, we show that
ISL-1 is recruited to the transcriptional region of the c-
Myc gene and activate its expression, which shed light
on the mechanism underlying the c-Myc dysregulation
and clinical lymphomagenesis.
The c-Jun N-terminal kinase (JNK) [21,26,28] and Janus
kinase/signal transducer and activator of transcription
(JAK/STAT) [29,44-47] signaling pathways, which are pre-
dicted to modulate ISL-1 expression, have been reported
to link to the oncogenic process of a variety of lymphoma
subtypes, making them appealing targets for pathway-directed cancer therapy. The application of specific sig-
naling pathways’ activators and inhibitors demonstrated
the correlation between JNK pathway and ISL-1, as well
JAK/STAT pathway and ISL-1 expression [21,24]. Figure 6
showed that ISL-1 expression was increased by elevated
c-Jun and STAT3 phosphorylation in Raji and Ly3 cells,
respectively. Reciprocally, attenuated p-c-Jun and p-STAT3
in these cells resulted in a decreased expression of ISL-1.
Furthermore, Pearson correlation analysis also revealed
strong correlation between the expression level of ISL-1
with p-STAT3 and p-c-Jun protein level in human NHL
samples. These data unequivocally linked ISL-1 expression
level with JNK and JAK/STAT signaling pathways.
Many reports suggest that c-Myc is a downstream ef-
fector of JNK or STAT3 signaling and c-Myc protein
level in NHL cells could be reduced in the presence of
JNK-specific siRNA or STAT3 shRNA [21,24]. However, it
remains to be determined whether p-c-Jun and p-STAT3
regulate the c-Myc expression directly or indirectly. Inter-
estingly, our data suggested that JNK and JAK/STAT
pathways could corporately regulate c-Myc expression
and promote lymphoma growth through up-regulating
the level of ISL-1. The overexpression of ISL-1 could res-
cue the growth suppression effect mediated by JNK and
JAK/STAT inhibitors, indicating that ISL-1 is necessary
for p-c-Jun and p-STAT3 effects. Therefore, ISL-1 might
be an important common mediator of c-Myc and JNK-
JAK/STAT signaling pathways in the progression of NHL.
In terms of regulatory mechanism of NHL, we demon-
strated that ISL-1 expression was regulated by both JNK
and JAK/STAT signaling pathways, p-STAT3/p-c-Jun/ISL-
1 could form a transcriptional complex and bind directly
to the ISL-1 promoter, indicating that ISL-1 might has a
positive feedback regulation. These conclusions are con-
sistent with previous reports that striking coincidences for
concerted aberrant activation of both STAT3 and c-Jun in
human cancer specimens are observed [31], and c-Jun or
c-Myc is required for the transforming activity of STAT3
in tumorgenesis [32,48]. Taken together, our results reveal
a functional linkage between JNK and JAK/STAT signaling
and the oncogenic roles of ISL-1 and c-Myc in NHL.Conclusions
Overall, in this study, we extend the knowledge about
the crucial roles of ISL-1. Our findings document that
ISL-1 is highly expressed in NHL and plays an onco-
genic role in lymphomagenesis. Aberrant ISL-1 could
stimulate cell proliferation and xenograft growth by acti-
vating c-Myc transcription. Moreover, JNK and JAK/STAT
pathways contribute to ISL-1 dysregulation. Our study
identifies a specific and novel function of ISL-1 in NHL
development and suggests that the ISL-1 suppression
represents a potential target for NHL treatment.
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Immunohistochemistry and immunohistologic analysis
All human samples were obtained from the Department
of Pathology, School of Basic Medical Sciences, Peking
University with the informed consent and with the
approval from the Research Ethics Committee of Peking
University (IRB 00001052–13014). The lymphoma tissue
microarrays (TMA) 203a and LY2086a were bought from
US Biomax (Rockville, MD, USA). Collected specimens
and TMA were subjected to immunohistochemistry (IHC)
analysis using the Enovision Detection Kit/DAB (GK50
0705, DAKO A/S, Glostrup, Denmark) according to the
manufacturer’s protocol with the indicated antibody:
mouse monoclonal anti-ISL-1 (ab86472, Abcam, Hong
Kong, China); rabbit polyclonal anti-c-Myc and anti-
phospho-c-Jun (Ser63) (E1A1002 and E1A3089, Eno-
Gene, China); rabbit monoclonal anti-phospho-Stat3
(Tyr705) (#9145, Cell Signaling Technology, Beverly,
MA, USA). Monoclonal mouse IgG2a and ployclonal
rabbit IgG (X0943 and X0936, DAKO A/S, Glostrup,
Denmark) were used as isotope controls.
A total of 10 to 20 areas (depending on the size of the
section) at 400× magnification of each section were
examined under microscopy, and the immunostaining was
assessed by two researchers independently in a blinded
fashion, i.e., without the knowledge of clinic pathologic
information. The expression level of ISL-1 in lymphomas
was scored semi-quantitatively based on the percentage of
positive cells and classified into negative (<25% neoplastic
cells stained positive), weak (25 ~ 49% neoplastic cells
stained positive), moderate (50 ~ 75% neoplastic cells
stained positive) and strong staining (>75% neoplastic
cells stained positive), which represent the score of 0, 1, 2
and 3. The images were acquired with a Leica DM25000B
microscope (Leica, Germany). The association between im-
munoreactivity and patient clinic pathological parameters
was assessed by χ2 test. Positive percent was determined by
number of strong staining samples (with ISL-1 expression
level scored 2 or 3) over the total number of samples.Cell culture and the establishment of stable cell lines
Diffuse large B cell lymphoma cell lines SUDHL16 and
Ly3 (gifts from Prof. Zhu J, Peking University Cancer
Hospital), Burkitt lymphoma cell lines (Raji, preserved
by our laboratory, and Ramos purchased from Cell Re-
source Center of Shanghai Institutes for Biological Sci-
ence, Shanghai, China), T-cell leukemia/lymphoma cell
line Jurkat (kindly provided by Prof. Ma DL, Peking Uni-
versity School of Basic Medical Sciences) were grown in
RPMI 1640 containing 10% fetal bovine serum. HeLa
cells (preserved by our laboratory) were cultured in
Dulbecco’s modified eagle medium supplemented with
10% fetal calf serum.To establish stable cell lines with ISL-1 overexpressing,
Raji, Ly3 and Jurkat cells were transfected with 10 μg
pcDNA3.1-ISL1 plasmid [6], or a control pcDNA3.1
plasmid, at a density of 1 × 107/ml, in a 0.2 cm cuvette
(BTX) using an BTX ECM803 Electroporator (Genetronics,
San Diego, CA, USA) at 130 V, 20 ms. G418 selection
(1000 μg/ml) was performed 48 h after transfection. The
cells were cultured for about 21 days to obtain stable cell
lines. The culture medium containing G418 was changed
every two days. To establish stable knockdown cell lines,
Ly3 and Jurkat cells were electroporated with pLL3.7-ISL1-
siRNA or pLL3.7-nonsilencer, respectively [6], and 48 h
after transfection, cells were cultured with a puromycin-
containing medium (0.5 μg/ml) for about 21 days.
Cell treatment, cell proliferation and cell cycle assays
STATTIC (sc-202818, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), SP600125 (s5567) and Anisomycin
(A9789) purchased from Sigma (Louis, MO, USA) were
dissolved in 100% dimethyl sulfoxide to prepare a 40 mM
stock, 20 mM stock and 15 mg/ml stock respectively, and
stored at −20°C. Recombinant human interleukin (IL)-6
purchased from R & D Systems (206IL, Minneapolis, MN,
USA) was reconstituted in sterile PBS containing 0.1%
bovine serum albumen to prepare a 10 μg/ml stock and
stored at −20°C. The stock solution was added in culture
medium to achieve the indicated final concentrations for
cell culture.
The cell proliferation was examined using a CCK-8
cell proliferation kit (Dojindo Laboratories, Kumamoto,
Japan), according to the instruction from the supplier.
Absorbance was measured at 450 nm with Microplate
Reader (Bio-Rad, La Jolla, CA, USA). After 24 hr serum
depletion (0.2% FBS), cells were subsequently incubated
in 10% FBS medium for an additional 24 hr before har-
vest. Cell cycle assessment and data analysis were carried
out referring to our previous report [6] using FACS Calibur
flow cytometry (Becton Dickinson, Franklin Lakes, NJ,
USA) equipped with the ModiFit LT v2.0 software.
Animal experiments
The animal experiments were performed in accordance
with the ethical principles and guidelines for scientific
experiments on animals of the Swiss Academy of Medical
Sciences (1995). All protocols were approved by the
Animal Care and Use Committee of Peking University
(LA 2010–066). Five-week-old NOD/SCID (nonobese
diabetic/severe combined immune deficient) mice were
purchase from the Department of Laboratory Animal
Science of Peking University. Six or five mice per group
were injected subcutaneously into the left and right
oxter flank with 1 × 107 cells resuspended in 200 μl PBS.
All mice were maintained under specific pathogen-free
conditions. Tumors were measured at indicated time
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length × width2. The mice were sacrificed by euthanasia
just before tumor skin festering and the tumors were
collected for further analysis. The significance of differ-
ences between groups was determined using the 2-way
ANOVA.
Luciferase assays
The plasmid transfection and luciferase activity detection
were performed as described before [30]. ISL-1-luc plas-
mid was constructed previously by our laboratory [30].
pCDNA3.1-c-Myc, c-Myc-luc was kindly provided by Prof.
Shang YF, Peking University School of Basic Medical Sci-
ences. c-Myc-luc M1, M2, D1 and D2 were commercially
constructed by TransGen Biotech (Beijing, China).
RT-PCR and real-time RT-PCR
Total RNA was extracted using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) based on the manufacturer’s instruc-
tions. RT-PCR and real-time RT-PCR amplifications
were performed as descripted before [30] with different
primers: ISL-1: F: 5′-CTGCTTTTCAGCAACTGGTCA-
3′, R: 5′-TAGGACTGGCTACCATGCTGT-3′; c-Myc: F:
5′-GCCACGTCTCCACACATCAG-3′, R: 5′-TCTTGGC
AGCAGGATAGTCCTT-3′; GAPDH: F: 5′-CGACCAC
TTTGTCAAGCTCA-3′, R: 5′-AGGGGTCTACATGGC
AACTG-3′.
Immunoprecipitation and Western blot analysis
Cell lysates were prepared using RIPA lysis buffer (P0013E,
Beyotime, Shanghai, China), which included protease and
phosphatase inhibitors (469313200, 14906845001, Roche,
Basle, Switzerland). Immunoprecipitation and Western
blot analysis were carried out as described before using
the indicated antibody [49]. Mouse monoclonal anti-
ISL-1 (H00003670-M05, Abnova, Taipei, China); rabbit
monoclonal anti-ISL-1 (3727–1, Eptomics an abcam
company, Hong Kong, China); rabbit monoclonal anti-
phosphor-JNK (Thr163/Tyr165) (#4668), rabbit monoclo-
nal anti-c-Myc (#5605), rabbit monoclonal anti-STAT3
and anti-phospho-STAT3 (Tyr705) (#4904 and #9145),
rabbit monoclonal anti-GAPDH (#2118) and anti-β-
tubulin (#2146) were all purchased from Cell Signaling
Technology (Beverly, MA, USA). Mouse monoclonal anti-
phospho-c-Jun (Ser63) (sc-822) and rabbit polyclonal
anti-c-Myc (sc-764) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Chromatin immunoprecipitation (ChIP) and ChIP-re-IP assays
ChIP and ChIP-re-IP experiments were performed in
Ly3 cells according to the method described by Zhang Y
et al. [50] using primers covering ISL-1 promoter region:
Primer 1: F: 5′-CCTTTCCTCCCACCCAACGTTTTTA-
3′, R: 5′-GCTTGGTTTGGTCCCCACG-3′; Primer 2: F:5′-GTGGGGACCAAACCAAGCTGAAC-3′, R: 5′-GGT
CCCCGCAGTCCGGCT-3′; Primer 3: F: 5′-AGGAGC
AGCGCCACAGGAG-3′, R: 5′-ATTATCATATTTCAGC
CTCGCCGC-3′; Primer 4: F: 5′-GCGGCGAGGCTGA
AATATGATAAT-3′, R: 5′-GCAGACTCGGCGCGGCT
C-3′; or primer covering c-Myc enhancer region: c-
Myc: F: 5′-TACAGTGCACTTTCACTAGTATTCA-3′,
R: 5′-TTATTGGAAATGCGGTCATG-3′.Statistical analysis
Statistical analyses were carried out using the statistical
software SPSS 17.0. The data are expressed as means ±
standard deviation (S.D.). Differences were considered to
be statistically significant at p < 0.05.Additional files
Additional file 1: Figure S1. ISL-1 is efficiently overexpressed or
knockdown in stably transfected NHL cells. ISL-1 expression was detected
by Western blot analysis in stably transfected Raji (A), Ly3 (B) and Jurkat
(C) cells. GAPDH served as an internal control. Representative images are
shown (A to C top panel) and the degree of ISL-1 expression changes
was calculated by gray scanning (A to C bottom panel) using the Bio-Rad
Quantity One software on the Western images from 3 independent
experiments. Each bar represents mean ± SD. p values were calculated
using a Student t-test (*p<0.05, **p<0.01, ##p<0.01, ###p<0.001).
Additional file 2: Figure S2. The ISL-1-overexpressing or -knockdown
cells produce significantly larger or smaller tumors than the control or
non-silencer cells. NOD-SCID mice were injected s.c. with different NHL cells
that were stably transfected with pcDNA3.1 (Control), or pcDNA3.1-ISL-1
(ISL-1) construct (A,C), pLL3.7-Non-silencer or pLL3.7-ISL1-siRNA plasmid
(B,D). The mice were killed after the last measurement of tumor volume
and the tumors were isolated and weighed. Statistical analysis was carried
out with 2-way ANOVA (*p<0.05, **p<0.01).
Additional file 3: Figure S3. ISL-1 expression level can be specifically
regulated by JNK and JAK/STAT signaling pathways. Western blot showed
the expression changes of ISL-1 in NHL cells after treated with WNT signaling
pathway inhibitor or activator (Frizzle, 10 μM or WNT3a protein, 100 ng/ml),
MAPK/ERK signaling pathway inhibitor (PD98059, 10 μM), P38/MAPK signaling
pathway inhibitor (SB203580, 10 μM), SAPK/JNK signaling pathway inhibitor
(SP600125, 10 μM), or JAK/STAT signaling pathway inhibitor (STATTIC, 6 μM)
for 24 h. The degree of ISL-1 expression changes was calculated by gray
scanning using the Bio-Rad Quantity One software on the Western images.
The data represent three independent experiments, each performed in
triplicate. Each bar represents mean ± SD (*p<0.05).
Additional file 4: Figure S4. The phosphorylation of c-Jun or STAT3 can
be inhibited by the specific JNK or JAK/STAT signaling pathway inhibitor,
respectively. Ly3 cells were treated with JNK signaling pathway inhibitor
(SP60012, 10 μM) or JAK/STAT signaling pathway inhibitor (STATTIC, 6 μM) for
indicated time. The inhibitory effect of SP600125 on c-Jun phosphorylation
(A) and the inhibitory effect of STATTIC on p-STAT3 phosphorylation (B) were
analyzed by Western blot. GAPDH served as an internal control.Competing interests
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